Innovative Therapies in Systemic Lupus Erythematosus
作者： Roberta Fenoglio , Fernando Fervenza , Dario Roccatello
DOI: 10.1007/978-3-319-24535-5_17
关键词:
摘要: Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with unpredictable course, periods of flares and remission. SLE characterized by broad spectrum clinical manifestations varying patterns disease activity. The efficacy current medication has been questioned treatment-related adverse side effects secondary to corticosteroid use untargeted immunosuppression the increasing number patients refractory disease. Over last decades, there major progress in understanding immunopathology SLE, paving way for development new biological agents, potentially revolutionizing treatment SLE. A variety novel therapeutic targets have identified many studies an attempt translate these treatments into practice.
springer.com
sci-hub.se 参考文章(86)
Ana Cristina Cordeiro, David A Isenberg, Novel therapies in lupus - focus on nephritis. Acta Reumatologica Portuguesa. ,vol. 33, pp. 157- 169 ,(2008)
Dario Roccatello, Savino Sciascia, Simone Baldovino, Daniela Rossi, Mirella Alpa, Carla Naretto, Debora Di Simone, Matteo Simoncini, Elisa Menegatti, A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment. Autoimmunity Reviews. ,vol. 14, pp. 1123- 1130 ,(2015) , 10.1016/J.AUTREV.2015.07.017
Fabien B Vincent, William A Figgett, Margaret L Hibbs, B-Cell Targeted Therapies in Systemic Lupus Erythematosus BioDrugs. ,vol. 27, pp. 85- 95 ,(2013) , 10.1007/S40259-013-0015-8
Mark S Cragg, Claire A Walshe, Andrey O Ivanov, Martin J Glennie, None, The biology of CD20 and its potential as a target for mAb therapy. Current directions in autoimmunity. ,vol. 8, pp. 140- 174 ,(2005) , 10.1159/000082102
T. Zhou, J. Zhang, R. Carter, R. Kimberly, BLyS and B cell autoimmunity. Current directions in autoimmunity. ,vol. 6, pp. 21- 37 ,(2002) , 10.1159/000066854
Pawel Traczewski, Lidia Rudnicka, Treatment of systemic lupus erythematosus with epratuzumab. British Journal of Clinical Pharmacology. ,vol. 71, pp. 175- 182 ,(2011) , 10.1111/J.1365-2125.2010.03767.X
David Wofsy, Jan L. Hillson, Betty Diamond, Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials Arthritis & Rheumatism. ,vol. 65, pp. 1586- 1591 ,(2013) , 10.1002/ART.37940
Jane A. Gross, Janet Johnston, Sherri Mudri, Rachel Enselman, Stacey R. Dillon, Karen Madden, Wenfeng Xu, Julia Parrish-Novak, Don Foster, Cathy Lofton-Day, Margaret Moore, Alisa Littau, Angelika Grossman, Harald Haugen, Kevin Foley, Hal Blumberg, Kim Harrison, Wayne Kindsvogel, Christopher H. Clegg, TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Nature. ,vol. 404, pp. 995- 999 ,(2000) , 10.1038/35010115
Eduardo F. Mysler, Alberto J. Spindler, Renato Guzman, Marc Bijl, David Jayne, Richard A. Furie, Frédéric A. Houssiau, Jorn Drappa, David Close, Romeo Maciuca, Kajal Rao, Saba Shahdad, Paul Brunetta, Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis & Rheumatism. ,vol. 65, pp. 2368- 2379 ,(2013) , 10.1002/ART.38037
Lena Schiffer, Ramalingam Bethunaickan, Meera Ramanujam, Weiqing Huang, Mario Schiffer, Haiou Tao, Michael M. Madaio, Erwin P. Bottinger, Anne Davidson, Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. Journal of Immunology. ,vol. 180, pp. 1938- 1947 ,(2008) , 10.4049/JIMMUNOL.180.3.1938